The first 60 days: Lower-risk myelodysplastic syndromes
Lower-risk myelodysplastic syndromes rarely turn into leukaemia quickly; the problem is anaemia and the transfusions it demands. Erythropoietin, then luspatercept (COMMANDS) and the telomerase blocker imetelstat (IMerge), free many patients from transfusions for months or years, and lenalidomide does the same for the del(5q) subtype. Below, week by week, is what OnCo's record of Lower-risk myelodysplastic syndromes says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- Medical oncologistNamed in the standard of care for: Anaemia, first line, Anaemia after erythropoietin or luspatercept failure.
- Palliative and supportive care teamNamed in the standard of care for: Asymptomatic, no transfusions, Anaemia, first line, Anaemia after erythropoietin or luspatercept failure, Supportive care.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Observation with blood counts every three to six months; no treatment.
Luspatercept for ring-sideroblast or SF3B1-mutated disease and for transfusion-dependent patients (COMMANDS); erythropoiesis-stimulating agent where serum erythropoietin is below 500 U/L; lenalidomide for del(5q).
Imetelstat (IMerge); luspatercept if not yet used; low-dose hypomethylating agent; trials of elritercept and other agents.
ImetelstatLuspaterceptAzacitidineA Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular BStudy of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic NeoplasmsRed cell transfusion to symptoms, iron chelation once ferritin is persistently high, G-CSF for recurrent neutropenic infection, platelet transfusion for bleeding.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example IPSS-R and IPSS-M scores, Serum erythropoietin level, Ring sideroblasts and SF3B1 mutation, del, Transfusion burden), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include MDS with low blasts, IPSS-R very low or low, MDS with SF3B1 mutation and ring sideroblasts, MDS with isolated del.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Asymptomatic, no transfusions
- For my situation (asymptomatic, no transfusions), which of the standard options do you recommend and why?Guideline options include: Observation with blood counts every three to six months; no treatment.
Anaemia, first line
- For my situation (anaemia, first line), which of the standard options do you recommend and why?Guideline options include: Luspatercept for ring-sideroblast or SF3B1-mutated disease and for transfusion-dependent patients (COMMANDS); erythropoiesis-stimulating agent where serum erythropoietin is below 500 U/L; lenalidomide for del(5q).
- Am I a candidate for Luspatercept, Epoetin alfa, Darbepoetin alfa or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Anaemia after erythropoietin or luspatercept failure
- For my situation (anaemia after erythropoietin or luspatercept failure), which of the standard options do you recommend and why?Guideline options include: Imetelstat (IMerge); luspatercept if not yet used; low-dose hypomethylating agent; trials of elritercept and other agents.
- Am I a candidate for Imetelstat, Luspatercept, Azacitidine, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular B and Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Supportive care
- For my situation (supportive care), which of the standard options do you recommend and why?Guideline options include: Red cell transfusion to symptoms, iron chelation once ferritin is persistently high, G-CSF for recurrent neutropenic infection, platelet transfusion for bleeding.
Any stage
- Are there clinical trials I could join, for example of Luspatercept, Imetelstat, A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular B, Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “No approved treatment for thrombocytopenia or neutropenia in lower-risk disease”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Whether early disease-modifying treatment changes the natural history rather than the transfusion count”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Trials open now for this cancer in OnCo, largest phase first. Joining a trial is a decision like any other: ask what the comparison arm is, whether a placebo is used, and what happens if you leave. The cancer page searches ClinicalTrials.gov live for more.
- A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular BPhase 3 · recruiting · NCT06499285A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)
- RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic NeoplasmsPhase 2 · active · NCT06243458A Phase II, Open-label, Multicenter Study of Orally Administered RVU120 for the Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms (MDS)
- Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and AnemiaPhase 1/2 · recruiting · NCT05320198RALLY-MF: A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)Phase 1/2 · recruiting · NCT05308264An Open-label, Phase 1b Study of R289, an IRAK1/4 Inhibitor, in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) Who Are Relapsed/Refractory/Resistant to Prior Therapies
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Lower-risk myelodysplastic syndromes: the full pageLower-risk myelodysplastic syndromes rarely turn into leukaemia quickly; the problem is anaemia and the transfusions it demands. Erythropoietin, then luspatercept (COMMANDS) and the telomerase blocker imetelstat (IMerge), free many patients from transfusions for months or years, and lenalidomide does the same for the del(5q) subtype.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC): Beyond the generic TNM system, gynaecological cancers (FIGO), lymphoma (Ann Arbor, IPI), myeloma (R-ISS), AML (ELN), kidney cancer (IMDC), neuroblastoma (INRG) and CLL (Rai, Binet) each have their own system that combines stage, blood tests, genetics and fitness into risk groups.
- Anaemia: A shortage of red blood cells or haemoglobin, causing tiredness and breathlessness.
- Ageing tissue and clonal fields: cancer as a disease of old tissue: Sequencing of healthy skin, gullet and blood shows that by middle age they are patchworks of mutant clones, many carrying classic cancer mutations, yet cancer stays rare until old age.
Every term links to the glossary.